TONI DELMONTE: Open Payments
NPI 1851098750 · MENIFEE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,907 in 92 payments from 12 companies in 2025. Trend: 2023 $350 · 2024 $1,220 · 2025 $1,907
Food & beverage: $1,907
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $521 |
| Neurocrine BioSciences, Inc. | 11 | $191 |
| Alkermes, Inc. | 9 | $184 |
| E.R. Squibb & Sons, L.L.C. | 9 | $174 |
| Vanda Pharmaceuticals Inc. | 8 | $173 |
| Otsuka America Pharmaceutical, Inc. | 9 | $167 |
| ABBVIE INC. | 6 | $136 |
| Teva Pharmaceuticals USA, Inc. | 10 | $135 |
| Supernus Pharmaceuticals, Inc. | 4 | $83 |
| Lundbeck LLC | 4 | $82 |
Products named: CAPLYTA, REXULTI, INGREZZA, COBENFY, VRAYLAR, ARISTADA, HETLIOZ, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
